We want to hear from you!

The Canadian Agency for Drugs and Technologies in Health (CADTH) is conducting a drug review for an MS treatment called peginterferon beta-1a. Marketed as Plegridy(TM) by Biogen, this drug is a new formulation of interferon beta-1a that enables it to last longer in the body, reducing the dosing schedule.

We need people living with MS and caregivers to take part in this important initiative by providing feedback on the impact the drug has had on their MS, or the potential impact this drug could have on their MS or on the MS of someone they are providing care for.

You can submit feedback by completing the MS Society’s patient input survey. Your responses will help to inform important health care decisions surrounding public coverage for and access to MS treatments.

One thought on “We want to hear from you!

  1. Debbie Shimming


    My name is Debbie Shimming. I am an accomplished administrative executive, as well as effective and efficient event planner, fundraiser and volunteer in the community. I am actively seeking employment in the not for profit sector. MS is a key non profit that I would like to work for and with, as many people I know are affected by this horrible disease. Can you please shed some light as to how I can work for this organization either remotely or in the city in which I live. I am crossed trained in several areas, and my experience and passion would be a great asset to the MS Society of Canada.


Leave a Reply

Your email address will not be published. Required fields are marked *